In 1981 Professor Colin Sullivan and colleagues at the University of Sydney described and developed nasal continuous positive airway pressure (CPAP), the first successful non-invasive treatment for obstructive sleep apnoea (OSA).
After publishing the successful results in Lancet, Sullivan, who had patented the technology, sought a compatible partner to help commercialise this life-changing technology. In 1986 he approached Chris Lynch, Managing Director of the Baxter Centre for Medical Research and Vice President of R&D for Baxter Healthcare, who in turn reached out to his Baxter co-worker Dr. Peter Farrell.
In 1987 Farrell, on behalf of Baxter, invested in Sullivan’s technology to further evolve the CPAP prototype and undertake clinical trials on a group of patients with severe sleep apnoea. In 1989, after Baxter decided not to enter the sleep apnoea market for a variety of reasons, Farrell founded ResMed (short for “Respiratory Medicine”) to buy Sullivan’s sleep technology from Baxter and to commercialise his prototype CPAP device to allow scalable device production – in other words, to bring CPAP to the world at large.
Since then, ResMed has delivered on Farrell’s promise: making CPAP masks, CPAP machines and in-home life support ventilators more comfortable, quieter and easier to use. It has also become the world leader in remote and self-monitoring software, with more than three million patients worldwide remotely monitored by clinicians. The software is shown to increase patients’ therapy adherence rates and clinicians’ business efficiencies.
Recent notable products include:
ResMed AirFit F20 internal Australian fitting study of existing CPAP patients conducted between March and April 2016.
ResMed AirFit F20 internal USA fitting study of existing CPAP patients conducted in April 2016.
ResMed AirFit F20 internal EU and APAC fitting study of existing CPAP patients conducted in June 2016.
ResMed AirFit N20 internal international fitting study of new and existing CPAP patients, conducted in Nov. 2015.